Jefferies Financial Group Inc. Has $1.97 Million Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Jefferies Financial Group Inc. raised its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 28.4% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 18,680 shares of the medical equipment provider's stock after purchasing an additional 4,133 shares during the period. Jefferies Financial Group Inc.'s holdings in Zimmer Biomet were worth $1,973,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Dodge & Cox lifted its holdings in shares of Zimmer Biomet by 12.0% during the 4th quarter. Dodge & Cox now owns 19,118,436 shares of the medical equipment provider's stock worth $2,019,480,000 after acquiring an additional 2,044,645 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in shares of Zimmer Biomet by 1.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,760,444 shares of the medical equipment provider's stock worth $1,559,147,000 after acquiring an additional 176,337 shares during the period. Van ECK Associates Corp lifted its holdings in shares of Zimmer Biomet by 5.9% during the 4th quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider's stock worth $417,814,000 after acquiring an additional 218,688 shares during the period. Franklin Resources Inc. lifted its holdings in shares of Zimmer Biomet by 398.7% during the 4th quarter. Franklin Resources Inc. now owns 3,497,764 shares of the medical equipment provider's stock worth $369,469,000 after acquiring an additional 2,796,372 shares during the period. Finally, Northern Trust Corp lifted its holdings in shares of Zimmer Biomet by 7.6% during the 4th quarter. Northern Trust Corp now owns 2,370,224 shares of the medical equipment provider's stock worth $250,367,000 after acquiring an additional 167,435 shares during the period. Institutional investors own 88.89% of the company's stock.

Zimmer Biomet Trading Down 1.3%

Shares of ZBH stock traded down $1.22 during trading hours on Friday, hitting $92.12. 3,505,131 shares of the company's stock traded hands, compared to its average volume of 1,804,829. The stock's 50 day simple moving average is $100.36 and its 200 day simple moving average is $104.92. The stock has a market cap of $18.23 billion, a PE ratio of 20.70, a price-to-earnings-growth ratio of 1.95 and a beta of 0.78. Zimmer Biomet Holdings, Inc. has a 12 month low of $89.92 and a 12 month high of $116.71. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.04. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. The company had revenue of $1.91 billion during the quarter, compared to analysts' expectations of $1.89 billion. During the same period in the prior year, the company posted $1.94 earnings per share. Zimmer Biomet's revenue for the quarter was up 1.1% compared to the same quarter last year. On average, sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Thursday, June 26th will be given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 1.04%. Zimmer Biomet's dividend payout ratio (DPR) is presently 21.24%.

Analyst Ratings Changes

ZBH has been the subject of a number of recent analyst reports. The Goldman Sachs Group cut their price target on shares of Zimmer Biomet from $120.00 to $104.00 and set a "neutral" rating for the company in a report on Tuesday, May 6th. Morgan Stanley cut their price target on shares of Zimmer Biomet from $115.00 to $95.00 and set an "equal weight" rating for the company in a report on Tuesday, May 6th. Robert W. Baird dropped their price objective on shares of Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating for the company in a research note on Tuesday, May 6th. JMP Securities dropped their price objective on shares of Zimmer Biomet from $140.00 to $125.00 and set a "market outperform" rating for the company in a research note on Wednesday, May 7th. Finally, Royal Bank of Canada dropped their price objective on shares of Zimmer Biomet from $125.00 to $112.00 and set an "outperform" rating for the company in a research note on Tuesday, May 6th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $111.53.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the firm's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the sale, the senior vice president now directly owns 8,768 shares in the company, valued at approximately $915,379.20. This trade represents a 14.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.70% of the stock is currently owned by corporate insiders.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.